MK-0646 IMPACT Study: MK-0646, Insulin Growth Factor 1 Receptor Antibody in Stage IIIB or IV Metastatic Non-Squamous Lung Cancer, Combined With Pemetrexed (Alimta) and Cisplatin, a Randomized Phase II Trial.
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2016
At a glance
- Drugs Dalotuzumab (Primary) ; Cisplatin; Pemetrexed
- Indications Lung cancer
- Focus Therapeutic Use
- Acronyms IMPACT
- 07 Jun 2017 Biomarkers information updated
- 06 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jan 2014 Planned End Date changed from 1 Nov 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov record.